Serbia: Around 250 New Cases of Hodgkin’s Lymphoma Diagnosed Annually Serbia diagnoses about 250 new Hodgkin’s lymphoma cases annually, with 40% found at advanced stages requiring complex treatment. Experts and patient associations are urging for the immediate implementation of targeted biological therapy in the first line of treatment, as current methods are over half a century old and carry severe long-term side effects. This shift is crucial to align with international standards and improve patient survival rates and quality of life.

• Approximately 250 new cases of Hodgkin’s lymphoma are diagnosed annually in Serbia.
• 40% of patients receive a diagnosis at an advanced stage, complicating treatment.
• Current first-line treatments in Serbia are over 50 years old and cause significant long-term side effects.
• Targeted biological therapy is highly effective in the first line, curing nearly all advanced cases according to clinical studies.
• In Serbia, targeted biological therapy is often only available after relapse, unlike in most European countries.
• Patient advocacy groups and medical professionals are calling for immediate access to modern therapies for better outcomes.
• Patient testimonials highlight severe health consequences from older, aggressive treatments, including organ damage and infertility.
• There is a significant discrepancy between treatment standards in Serbia and neighboring countries, leading to patient concern.